Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Schering-Plough

- PMLiVE

Keytruda cleared for melanoma in Europe

Merck’s new PD-1 drug will compete against rival BMS for market share

- PMLiVE

Merck plans expanded filing for Emend this year

Nausea and vomiting therapy more effective than placebo in 1000-patient trial

- PMLiVE

Merck & Co’s diabetes drug Januvia cleared by CV safety trial

Concerns over the DPP-4 inhibitor 'put to bed' by TECOS cardiovascular trial

- PMLiVE

FDA gives priority review for Keytruda in lung cancer

The regulator is expected to deliver a verdict by October 2 

- PMLiVE

Amgen and Merck to expand cancer collaboration

Firms to test Keytruda in combination for cancers inside the head and neck

Bristol-Myers Squibb (BMS) building

BMS melanoma combo impresses at ASCO

Increases survival in difficult to treat form of skin cancer

- PMLiVE

Merck files all-oral hepatitis C therapy in US

Seeking approval for grazoprevir and elbasvir, which already has FDA breakthrough status

- PMLiVE

Merck’s breakthrough HCV drug aces trial

Grazoprevir/elbasvir showed efficacy in phase II and III trials

- PMLiVE

Merck files Keytruda for lung cancer

Filed to the FDA as a treatment option for NSCLC patients

- PMLiVE

Merck appoints head of combined life science business

Udit Batra is CEO and president of Merck Millipore

- PMLiVE

Pfizer and Merck flesh out Xalkori alliance details

First stage of building a combined oncology sales organisation

- PMLiVE

PD-1 cancer market overrated, says new report

The immuno-oncology market for new oncology drugs may be worth half of current expectations

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links